Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial
A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.
A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.
Researchers have been studying PGS as a germline biomarker for prostate cancer risk, Kader explains. The PLCO trial randomized 75,000 men to either receive screening or not for disease. Data was obtained through the screened arm.
It was demonstrated that the PGS test for prostate cancer risk was valid within that cohort. Additionally, researchers were able to stratify men for their risk of disease within the screened group, as well as improve PSA performance. Therefore, men with a higher risk of disease had a clinically more meaningful PSA score.
